drugset
drugset / Trial / NCT02057692

Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome

NCT02057692 ↗

Phase 2 Completed 37 enrolled Mirum Pharmaceuticals, Inc. Childhood Liver Disease Research and Education Network · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

The study is a randomized, double-blind, placebo-controlled study in children with Alagille Syndrome (ALGS). The study will investigate the effects of LUM001, compared to placebo, on pruritus, serum bile acids, liver enzymes, and other biochemical markers in patients with ALGS.

Timeline

Start
2014-11-24
Primary completion
2016-11-16
Completion
2016-11-16

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Maralixibat Small molecule — Oral

Indications

Alagille syndrome